Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

Efficacy and Safety of Bismuth-containing Quadruple Therapy for First Line Helicobacter Pylori Eradication: A Multicenter Retrospective Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07167511

Acronym

RETRO-HP

Enrollment

1730

Registered

2025-09-11

Start date

2022-01-01

Completion date

2025-07-31

Last updated

2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori Infection

Keywords

Helicobacter pylori, quadruple therapy

Brief summary

Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various bismuth-containging quadruple regimens and identify factors influencing treatment failure. A multicenter retrospective analysis was conducted and study outcomes included eradication rates and incidence of adverse events.

Interventions

OTHERThis study is a retrospective study, and all data have been collected in advance with no active intervention required.

This study is a retrospective study, and all data have been collected in advance with no active intervention required.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* patients aged 18-70 years, regardless of gender; * absent history of receiving H. pylori eradication therapy; * diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination.

Exclusion criteria

* patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments; * patients who received treatment regimens that did not comply with the quadruple regimens specified in this study.

Design outcomes

Primary

Measure	Time frame	Description
Eradication rate	6 weeks after treatment completion	Comparison of eradication rates among quadruple therapies for Helicobacter pylori

Secondary

Measure	Time frame
Adverse events	Immediately after treatment completion

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026